[{"orgOrder":0,"company":"Gan & Lee Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Bempedoic Acid","moa":"ATP-citrate synthase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"Gan & Lee Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Gan & Lee Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Gan & Lee Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Gan & Lee Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"GLR2007","moa":"Cyclin-dependent kinase 4 (CDK4)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Gan & Lee Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Gan & Lee Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Gan & Lee Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Gan & Lee Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"GLR2007","moa":"Cyclin-dependent kinase 4 (CDK4)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Gan & Lee Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Gan & Lee Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Gan & Lee Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Gan & Lee Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"GLR2007","moa":"Cyclin-dependent kinase 4 (CDK4)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Gan & Lee Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Gan & Lee Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Gan & Lee Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Gan & Lee Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"GLR2007","moa":"Cyclin-dependent kinase 4 (CDK4)","graph1":"Oncology","graph2":"Phase I","graph3":"Gan & Lee Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Gan & Lee Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Gan & Lee Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Gan & Lee Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"GZR18","moa":"Glucagon-like peptide 1 receptor (GLP1R)","graph1":"Endocrinology","graph2":"Phase III","graph3":"Gan & Lee Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Gan & Lee Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Gan & Lee Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Gan & Lee Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"GZR4","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase III","graph3":"Gan & Lee Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous","sponsorNew":"Gan & Lee Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Gan & Lee Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Gan & Lee Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"GZR4","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase III","graph3":"Gan & Lee Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous","sponsorNew":"Gan & Lee Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Gan & Lee Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Gan & Lee Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"GZR4","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase III","graph3":"Gan & Lee Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous","sponsorNew":"Gan & Lee Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Gan & Lee Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Gan & Lee Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"GZR18","moa":"Glucagon-like peptide 1 receptor (GLP1R)","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Gan & Lee Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Gan & Lee Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Gan & Lee Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Gan & Lee Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Insulin Lispro","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Gan & Lee Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Gan & Lee Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Gan & Lee Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Gan & Lee Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"GZR18","moa":"Glucagon-like peptide 1 receptor (GLP1R)","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Gan & Lee Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Gan & Lee Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Gan & Lee Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Gan & Lee Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"GZR18","moa":"Glucagon-like peptide 1 receptor (GLP1R)","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Gan & Lee Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Gan & Lee Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Gan & Lee Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Gan & Lee Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"GZR18","moa":"Glucagon-like peptide 1 receptor (GLP1R)","graph1":"Endocrinology","graph2":"Phase III","graph3":"Gan & Lee Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Gan & Lee Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Gan & Lee Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Gan & Lee Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Peptide","year":"2025","type":"Inapplicable","leadProduct":"Bofanglutide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Gan & Lee Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Gan & Lee Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Gan & Lee Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Gan & Lee Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Bofanglutide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Gan & Lee Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Gan & Lee Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Gan & Lee Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Gan & Lee Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"GZR101","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase II","graph3":"Gan & Lee Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Gan & Lee Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Gan & Lee Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Gan & Lee Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"GZR4","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase II","graph3":"Gan & Lee Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Gan & Lee Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Gan & Lee Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Gan & Lee Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"GZR18","moa":"Glucagon-like peptide 1 receptor (GLP1R)","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Gan & Lee Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Gan & Lee Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Gan & Lee Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Gan & Lee Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"GZR18","moa":"Glucagon-like peptide 1 receptor (GLP1R)","graph1":"Endocrinology","graph2":"Phase III","graph3":"Gan & Lee Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Gan & Lee Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Gan & Lee Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Gan & Lee Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"GZR4","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase III","graph3":"Gan & Lee Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous","sponsorNew":"Gan & Lee Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Gan & Lee Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Gan & Lee Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"GZR4","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase III","graph3":"Gan & Lee Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous","sponsorNew":"Gan & Lee Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Gan & Lee Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Gan & Lee Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"GZR4","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase III","graph3":"Gan & Lee Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous","sponsorNew":"Gan & Lee Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Gan & Lee Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Gan & Lee Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"GZR18","moa":"Glucagon-like peptide 1 receptor (GLP1R)","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Gan & Lee Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Gan & Lee Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Gan & Lee Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Gan & Lee Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Insulin aspart","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase I","graph3":"Gan & Lee Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous","sponsorNew":"Gan & Lee Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Gan & Lee Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Gan & Lee Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Hormone","year":"2021","type":"Inapplicable","leadProduct":"Insulin aspart","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase I","graph3":"Gan & Lee Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"Gan & Lee Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Gan & Lee Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Gan & Lee Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Insulin Lispro","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase I","graph3":"Gan & Lee Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Gan & Lee Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Gan & Lee Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Gan & Lee Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Insulin Glargine","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase III","graph3":"Gan & Lee Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Gan & Lee Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Gan & Lee Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Gan & Lee Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Bofanglutide","moa":"GLP-1 receptor","graph1":"Endocrinology","graph2":"Phase I","graph3":"Gan & Lee Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Gan & Lee Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Gan & Lee Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Gan & Lee Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Bofanglutide","moa":"GLP-1 receptor","graph1":"Endocrinology","graph2":"Phase I","graph3":"Gan & Lee Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Gan & Lee Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Gan & Lee Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Gan & Lee Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"GZR33","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Gan & Lee Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Gan & Lee Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Gan & Lee Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Gan & Lee Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Peptide","year":"2025","type":"Inapplicable","leadProduct":"GZR18","moa":"Glucagon-like peptide 1 receptor (GLP1R)","graph1":"Endocrinology","graph2":"Phase III","graph3":"Gan & Lee Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gan & Lee Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Gan & Lee Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Gan & Lee Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Peptide","year":"2025","type":"Inapplicable","leadProduct":"GZR18","moa":"Glucagon-like peptide 1 receptor (GLP1R)","graph1":"Endocrinology","graph2":"Phase III","graph3":"Gan & Lee Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gan & Lee Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Gan & Lee Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Gan & Lee Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"GZR101","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Phase II","graph3":"Gan & Lee Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Gan & Lee Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Gan & Lee Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Gan & Lee Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"GZR18","moa":"Glucagon-like peptide 1 receptor (GLP1R)","graph1":"Endocrinology","graph2":"Phase III","graph3":"Gan & Lee Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gan & Lee Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Gan & Lee Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Gan & Lee Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"GZR18","moa":"Glucagon-like peptide 1 receptor (GLP1R)","graph1":"Endocrinology","graph2":"Phase III","graph3":"Gan & Lee Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gan & Lee Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Gan & Lee Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Gan & Lee Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"GZR18","moa":"Glucagon-like peptide 1 receptor (GLP1R)","graph1":"Endocrinology","graph2":"Phase III","graph3":"Gan & Lee Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gan & Lee Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Gan & Lee Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Gan & Lee Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"GZR4","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Gan & Lee Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Gan & Lee Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Gan & Lee Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Gan & Lee Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"GZR33","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Gan & Lee Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Gan & Lee Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Gan & Lee Pharmaceuticals \/ Inapplicable"}]
Find Clinical Drug Pipeline Developments & Deals by Gan & Lee Pharmaceuticals
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
